Clinical Trials
130 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ModernaTX, Inc.
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
PanRAF
Royal Marsden NHS Foundation Trust
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
NST-628
Nested Therapeutics, Inc
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
MK-4700-001
Merck Sharp & Dohme LLC
PALANGI3
Centre Oscar Lambret
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Werewolf Therapeutics, Inc.
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
AbbVie
ACT
AgonOx, Inc.
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
ON-5001
OncoNano Medicine, Inc.
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
Chiome Bioscience Inc.
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
University of Pittsburgh
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Scholar Rock, Inc.
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Tvardi Therapeutics, Incorporated
Meteor 1
GlaxoSmithKline
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Altor BioScience
IVY
Eli Lilly and Company
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Astellas Pharma Inc
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
University of California, San Diego
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
TuHURA Biosciences, Inc.
A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin
Rockefeller University
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
R-Pharm